Farxiga International Purchase Legalities: What You Need to Know in 2026

What Federal Law Actually Says About Importing Farxiga

The short answer: importing Farxiga from another country for personal use is technically illegal under the Federal Food, Drug, and Cosmetic Act (FD&C Act), but the FDA exercises discretionary enforcement in narrow circumstances. Understanding the difference between "technically prohibited" and "actively prosecuted" is the starting point for any honest discussion of this topic.

The FD&C Act Baseline

Under 21 U.S.C. §331 and §381, drugs not approved for US sale or not in compliance with US labeling requirements are subject to refusal of entry at the border. [1] Farxiga sold in Canada, the UK, or the EU carries different labeling, lot numbers, and sometimes different inactive ingredient profiles than the FDA-approved US version, even though the active molecule (dapagliflozin) is identical. That distinction is enough to make the foreign product technically unapproved for import.

The FDA's own import guidance states that the agency "may" allow personal importation when the product is for a serious condition, no US equivalent is available, the quantity is a personal-use supply (generally up to a 90-day supply), and the importer provides contact information for a US physician. [2] Farxiga is available domestically, which means the "no US equivalent" prong typically cannot be met. The FDA does not guarantee admission of any shipment.

What "Discretionary Enforcement" Means in Practice

Discretionary enforcement means FDA inspectors at mail facilities and ports of entry may choose not to detain a small personal-use shipment, but they are under no obligation to release it. [2] Shipments can be seized without warning. The importer has no legal recourse if a shipment is destroyed. A 2023 FDA import alert (Import Alert 66-41) specifically names categories of unapproved drugs mailed from foreign countries; while Farxiga itself is not individually listed, the alert class covers unapproved versions of approved drugs. [3]

Criminal Liability

Criminal prosecution for a first-time, small personal-use import is rare, but not impossible. Commercial-scale importation (multiple bottles, resale intent) carries felony exposure under 21 U.S.C. §333. [1] Anyone purchasing Farxiga for a family member or friend, or buying in bulk to share costs, moves from the personal-use gray zone into territory prosecutors have pursued.

State-Authorized Importation Programs: Section 804

Section 804 of the FD&C Act, amended by the Medicare Modernization Act of 2003, authorizes the HHS Secretary to allow importation from Canada if it poses no additional risk to public health and results in significant cost savings. [4] After nearly two decades of inaction, Florida's Section 804 Importation Program (SB4IP) received FDA approval in January 2024, making it the first state-level program to gain federal sign-off. [5]

How Florida's Program Works

Florida's program is designed for state agencies and managed-care organizations, not individual consumers walking into a pharmacy. The state contracts with Canadian wholesale suppliers and distributes covered drugs through specific dispensing channels. As of early 2026, dapagliflozin (Farxiga) is under review for inclusion in Florida's formulary; the state's list prioritizes high-volume, high-cost drugs with large price differentials. [5]

Other states with active or pending Section 804 applications include Colorado, New Mexico, and Texas. [6] None of these programs, as currently structured, allow a private individual to order directly from a Canadian pharmacy and call it authorized importation.

What This Means for Individual Patients

If your state's Section 804 program covers dapagliflozin, you may eventually receive it through a participating health plan or state program at a substantially lower cost. You cannot, however, use a state's Section 804 authorization as personal legal cover for ordering Farxiga from a Canadian online pharmacy. The two mechanisms are entirely separate. [4]

Canadian Online Pharmacies: Separating Verified From Fraudulent

Canadian pharmacies are not all equivalent. The term "Canadian pharmacy" covers everything from licensed provincial dispensaries to offshore operations that merely use Canadian-sounding names while shipping from India, China, or Eastern Europe. [7]

How to Identify a Legitimate Canadian Pharmacy

The Canadian International Pharmacy Association (CIPA) maintains a verified member list at cipa.com. CIPA-certified pharmacies require a valid prescription, dispense Health Canada-approved products, and employ licensed pharmacists. A 2019 FDA analysis found that of 85 online pharmacies sampled, 72 (85%) violated state or federal laws, and many claiming Canadian origin actually shipped from unregulated overseas sources. [7]

Verification steps before any purchase:

• Confirm CIPA membership directly on the CIPA site, not on the pharmacy's own page.
• Check that the pharmacy requires a prescription faxed or mailed from a US-licensed physician.
• Look for a physical street address and Canadian provincial pharmacy license number.
• Avoid any site offering dapagliflozin without a prescription, offering prices below $80 CAD per 30 tablets, or accepting only cryptocurrency or wire transfer.

Counterfeit Dapagliflozin: A Real Risk

The FDA's BeSafeRx program documents cases of counterfeit cardiovascular and diabetes drugs sold through unverified online pharmacies. [8] Subpotent dapagliflozin is clinically dangerous: patients with type 2 diabetes, heart failure with reduced ejection fraction (HFrEF), or chronic kidney disease (CKD) depend on consistent SGLT2 inhibition. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% vs. Placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001). [9] A counterfeit or subpotent tablet undermines that outcome data entirely.

How to Get Farxiga Cheaper: Legitimate US-Based Options

The safest and most legally defensible cost-reduction strategies do not involve crossing international lines. Several options can reduce out-of-pocket cost dramatically.

AstraZeneca's Farxiga Savings Card

AstraZeneca offers a copay savings card for commercially insured patients. Eligible patients pay as little as $10 per 30-day supply for up to 24 months. [10] The card is not usable by patients with Medicare, Medicaid, or any federal or state government-sponsored insurance. Enrollment is available at farxiga.com/savings. Income-based eligibility for uninsured patients is handled separately through AstraZeneca's AZ&Me prescription savings program, which can provide Farxiga at no cost to qualifying patients earning up to 600% of the federal poverty level. [10]

GoodRx, RxSaver, and Pharmacy Discount Programs

GoodRx coupons for dapagliflozin 10 mg (30 tablets) ranged from approximately $480 to $580 at major US chains as of late 2025, representing 10 to 25% savings off retail. These coupons are not insurance and cannot be combined with insurance benefits at the point of sale, but they are legal, instantaneous, and require no enrollment. [11]

Mark Cuban Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) listed dapagliflozin 10 mg at approximately $29 per 30 tablets as of January 2026, a reduction of roughly 95% from list price. [12] Cost Plus operates as a licensed US pharmacy, ships to most states, and requires a valid prescription. This is the single largest documented cost reduction available to uninsured or underinsured US patients without navigating international law.

Patient Assistance Programs Through NeedyMeds

NeedyMeds (needymeds.org) maintains a continuously updated database of manufacturer and nonprofit assistance programs. [13] For patients who do not qualify for the AstraZeneca savings card, NeedyMeds lists third-party co-pay assistance foundations that cover SGLT2 inhibitors, including dapagliflozin, for patients with Medicare Part D.

HSA and FSA Eligibility for Farxiga

Farxiga is a prescription medication, which makes it an eligible medical expense under IRS Publication 502. [14] Both Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) can be used to pay for dapagliflozin at any licensed US pharmacy.

Practical HSA/FSA Considerations

You can use HSA or FSA funds to pay the copay remaining after insurance, the full retail price if uninsured, or the discounted price obtained through a savings card or GoodRx coupon. You cannot use HSA/FSA funds to pay for Farxiga purchased from an unverified foreign pharmacy, because IRS rules require the drug to be "legally obtained." [14] A shipment that crosses the border outside the FDA's discretionary exception would not qualify.

The IRS does not police individual HSA transactions in real time, but documentation matters. If audited, you would need to show a valid prescription and a receipt from a licensed pharmacy. An overseas wire transfer to a foreign pharmacy does not constitute adequate documentation under IRS Publication 502 guidance. [14]

Triple-Tax Advantage Still Applies

When paying for Farxiga through an HSA, the triple-tax advantage (pre-tax contributions, tax-free growth, tax-free qualified withdrawals) applies in full. [14] For a patient in the 22% federal bracket paying $600/month for Farxiga, shifting that expense to an HSA saves approximately $132/month in federal income tax, or $1,584 annually, before any state income-tax benefit.

Dapagliflozin Pricing Outside the US: The Price Gap That Drives Import Interest

The price differential between the US and other markets is real and substantial. In the UK, the National Health Service acquires dapagliflozin through negotiated tender pricing at approximately £1.50, £2.50 per tablet (roughly $2, $3 USD). [15] In Canada, Health Canada-approved Forxiga (the Canadian brand name) retails at approximately CAD $3.50, $5.00 per tablet through provincial formularies. The US list price of roughly $19, $22 per tablet represents a 6-to-10-fold markup. [16]

This gap is a policy reality documented in peer-reviewed literature. A 2021 JAMA Internal Medicine analysis found that US net prices for brand-name drugs were on average 2.56 times higher than in 10 other high-income countries, with some drugs showing differentials exceeding 10-fold. [16] Dapagliflozin was among the top-quartile drugs by price differential in that analysis.

The HealthRX Access Framework for dapagliflozin categorizes cost-reduction options by legal risk and accessibility:

| Option | Legal Risk | Monthly Savings (est.) | Prescription Required | |---|---|---|---| | AstraZeneca savings card (commercially insured) | None | $580, $610 vs. List | Yes | | Cost Plus Drugs | None | $550, $580 vs. List | Yes | | GoodRx coupon | None | $50, $150 vs. List | Yes | | AZ&Me (uninsured, income-qualifying) | None | Full cost | Yes | | State Section 804 program (if formulary-listed) | None | Variable | Yes | | CIPA-verified Canadian pharmacy (personal import) | Low-moderate (seizure risk) | $300, $450 vs. List | Yes | | Unverified "Canadian" online pharmacy | High (seizure, counterfeit, fraud) | Variable | Often not required |

Regulatory Approval History and Indication Scope

Understanding what Farxiga is approved for matters for cost and access discussions, because indication affects insurance coverage tiers.

FDA Approvals by Indication

The FDA approved dapagliflozin (Farxiga) for type 2 diabetes on January 8, 2014, at doses of 5 mg and 10 mg daily. [17] On May 5, 2020, the FDA extended approval to heart failure with reduced ejection fraction (HFrEF) in adults, regardless of diabetes status. [18] On April 30, 2021, a further indication for chronic kidney disease (CKD, stages 2 to 4 with albuminuria) was approved, based primarily on the DAPA-CKD trial. [19]

DAPA-CKD Trial Data

The DAPA-CKD trial (N=4,304) showed dapagliflozin 10 mg reduced the composite of sustained 50% decline in eGFR, end-stage kidney disease, or renal or cardiovascular death by 39% vs. Placebo (HR 0.61; 95% CI 0.51 to 0.72; P<0.001). [19] The trial was stopped early for efficacy at a planned interim analysis. These data directly inform insurance coverage decisions: payers covering CKD-stage patients may reimburse at a different tier than for type 2 diabetes alone.

European and UK Approval Context

The European Medicines Agency (EMA) approved dapagliflozin (Forxiga) under centralized procedure for type 2 diabetes in November 2012, two years before the FDA. [20] The EMA subsequently approved HFrEF and CKD indications on timelines broadly similar to the FDA. This chronology explains why dapagliflozin has a longer generic-competition runway in Europe: the EU data-exclusivity period is 10 years from first approval, meaning generic entry in the EU was legally possible from late 2022 in some member states.

Importation From Mexico: A Separate Legal Framework

Mexico is not Canada. The Section 804 pathway applies only to Canada. [4] Importation from Mexican pharmacies is governed solely by FDA's general personal-importation policy, with no statutory framework for authorized state programs. [2]

Mexican pharmacies sometimes stock dapagliflozin at prices closer to Canadian levels, and travelers physically crossing the border with a 90-day personal supply occupy a different practical risk category than mail shipments. The FDA's personal-importation guidance mentions that the agency generally does not pursue travelers carrying personal-use quantities across land borders. [2] This is still discretionary and provides no legal guarantee.

Purchasing from a Mexican online pharmacy and having the product shipped by mail places the transaction squarely back under Import Alert 66-41 exposure. [3]

Telehealth and the Prescription Requirement

Every legitimate pathway to dapagliflozin, domestic or international, requires a valid prescription from a licensed prescriber. The DEA and state medical boards have specific rules about prescribing controlled substances via telehealth, but dapagliflozin is not a controlled substance. A telehealth visit with a board-certified US physician who holds a license in your state is sufficient to generate a valid Farxiga prescription. [21]

That prescription can then be used at Cost Plus Drugs, with a GoodRx coupon at a local pharmacy, through the AstraZeneca savings card, or mailed to a CIPA-verified Canadian pharmacy if the patient accepts the legal and practical risks outlined above.

The ADA's 2025 Standards of Care in Diabetes recommend SGLT2 inhibitors, including dapagliflozin, as preferred add-on therapy for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, regardless of HbA1c level. [22] That guideline language strengthens the case for insurance coverage and prior-authorization appeals when payers restrict access.

Prior Authorization and the Appeals Process

Most commercial insurers and Medicare Part D plans require prior authorization (PA) for Farxiga. [23] A PA denial is not the end of the road.

Step-Therapy Requirements

Many plans require a trial of metformin and one other oral agent (typically a sulfonylurea or DPP-4 inhibitor) before approving an SGLT2 inhibitor. If your prescriber has clinical grounds for bypassing step therapy (for example, established HFrEF where an SGLT2 inhibitor is guideline-directed), a PA exception request citing the 2025 ADA Standards of Care and the DAPA-HF trial outcome data is a legitimate and often successful approach. [9, 22]

How to Request an Exception

Your prescriber's office submits a PA exception request with supporting documentation. The request should include your current diagnosis codes, relevant lab values (eGFR for CKD, echocardiogram results for HFrEF, HbA1c for diabetes), and a letter of medical necessity citing guideline-concordant care. Insurers are required under the Affordable Care Act to have an internal appeals process and, if that fails, an external independent review. [23] Patients who win PA appeals for SGLT2 inhibitors documented in a 2022 JAMA Internal Medicine analysis received approvals in 72% of cases when appeals included clinical guideline citations. [24]

What HealthRX Recommends

The cheapest legal path to Farxiga for most uninsured or underinsured US patients in 2026 is Cost Plus Drugs, which lists dapagliflozin 10 mg at approximately $29 per 30 tablets with a valid US prescription. [12] For commercially insured patients, the AstraZeneca savings card brings cost to $10/month. [10] For Medicare patients ineligible for manufacturer savings cards, third-party foundations listed on NeedyMeds or the Extra Help low-income subsidy program through Social Security can cover most or all of Part D cost-sharing. [13]

International purchase from a CIPA-verified Canadian pharmacy remains a gray-zone option that carries real seizure risk, no legal guarantee, and no HSA/FSA documentation pathway. The price differential is real, but the legal and practical infrastructure to capture it safely, at the individual-patient level, does not yet exist in the US. Florida's Section 804 program may change that for CMS-covered patients in participating health plans. Track that program's formulary updates at fdaimportprograms.fda.gov. [5]